Evidence map›Paper›PMID 19636696›Full record

Trial reportArchives of sexual behavior2010

Covert use, vaginal lubrication, and sexual pleasure: a qualitative study of urban U.S. Women in a vaginal microbicide clinical trial.

Susie Hoffman, Kate M Morrow, Joanne E Mantell, Rochelle K Rosen, Alex Carballo-Diéguez, Fang Gai

Abstract readClinical Trial
In one paragraph

Trial report in Archives of sexual behavior, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Achieving the optimal vaginal state: using vaginal products and study gels in Uganda, Zimbabwe, and South Africa.International journal of sexual health : official journal of the World Association for Sexual Health · 2017
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Microbicide clinical trial adherence: insights for introduction.Journal of the International AIDS Society · 2013
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Susie HoffmanHIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute and Columbia University, 1051 Riverside Drive, Unit 15, New York, NY 10032, USA. sh51@columbia.edu
Kate M Morrow
Joanne E Mantell
Rochelle K Rosen
Alex Carballo-Diéguez
Fang Gai

Funding

HIV PREVENTION TRIALS NETWORK LEADERSHIP GROUPU01AI046749 · NIAID · FAMILY HEALTH INTERNATIONAL · PI CATES, WILLARD · 1999 to 2005
$73.5M
HIV PREVENTION TRIALS NETWORK LEADERSHIP GROUPU01AI046702 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI FLEMING, THOMAS R · 2000 to 2005
$49.5M
The Statistics, Data Science, and Data Management (SDM) CoreP30MH043520 · NIMH · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI Claude Ann Mellins · 2003 to 2026
$48.2M
HIV PREVENTION TRIAL UNITU01AI048014 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI METZGER, DAVID S · 2000 to 2006
$20.9M
HPTN CENTRAL LABORATORYU01AI046745 · NIAID · JOHNS HOPKINS UNIVERSITY · PI JACKSON, JAY B · 2000 to 2005
$20.8M
UAB-ZAMBIA-HAITI HIV PREVENTION TRIALS UNITU01AI047972 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI STRINGER, JEFFREY SAMUEL ALLEN · 2000 to 2006
$16.5M
HIV PREVENTION TRIAL UNITSU01AI048040 · NIAID · FENWAY COMMUNITY HEALTH CENTER · PI MAYER, KENNETH H · 2000 to 2007
$11.5M
HIV PREVENTION TRIAL UNIT (PRIDE NYC PROGRAM)U01AI048016 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI EL-SADR, WAFAA M. · 2000 to 2006
$7.8M
NIAID NIH HHS U01 AI046702NIAID NIH HHS U01 AI046745NIAID NIH HHS U01 AI046749NIAID NIH HHS U01 AI047972NIAID NIH HHS U01 AI048014NIAID NIH HHS U01 AI048016NIAID NIH HHS U01 AI048040NIAID NIH HHS U01-AI-46702NIAID NIH HHS U01-AI-46745NIAID NIH HHS U01-AI-46749NIAID NIH HHS U01-AI-47972NIAID NIH HHS U01-AI-48014NIAID NIH HHS U01-AI-48016NIAID NIH HHS U01-AI-48040NIMH NIH HHS P30 MH043520NIMH NIH HHS P30-MH43520
6 · The paper itself

Abstract

Using data from a U.S. clinical safety trial of tenofovir gel, a candidate microbicide, we explored the intersection of sexual pleasure and vaginal lubrication to understand whether and under what circumstances women would use a microbicide gel covertly with primary partners. This study question emerged from acceptability research in diverse settings showing that even though future microbicides are extolled as a disease prevention method that women could use without disclosing to their partners, many women assert they would inform their primary partner. Participants (N = 84), stratified by HIV-status and sexual activity (active vs. abstinent), applied the gel intra-vaginally for 14 days. At completion, quantitative acceptability data were obtained via questionnaire (N = 79) and qualitative data via small group discussions (N = 15 groups, 40 women). Quantitatively, 71% preferred a microbicide that could not be noticed by a sex partner and 86% experienced greater vaginal lubrication with daily use. Based on our analysis of the qualitative data, we suggest that women's perception that their primary partners would notice a microbicide gel is a more important reason for their caution regarding covert use than may previously have been recognized. Our findings also showed that women's assessment of the possibility of discreet, if not covert, use was strongly related to their perception of how a microbicide's added vaginal lubrication would influence their own and their partner's pleasure, as well as their partner's experience of his sexual performance. A microbicide that increases pleasure for both partners could potentially be used without engendering opposition from primary partners.

Indexed as

Sexual PartnersAdenineAdministration, IntravaginalAdultAnti-HIV AgentsAnti-Infective Agents, LocalBlack or African AmericanCohort StudiesCoitusFemaleHeterosexualityHIV InfectionsHumansInterpersonal RelationsInterviews as TopicLubricantsAdenineAnti-HIV AgentsAnti-Infective Agents, LocalLubricantsOrganophosphonatesTenofovirVaginal Creams, Foams, and Jellies

Identifiers

PMID19636696
PMCPMC2855760

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.